StockNews.AI
EW
StockNews.AI
13 days

JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition

1. FTC blocks Edwards Lifesciences' proposed acquisition of JenaValve. 2. JenaValve intends to legally challenge FTC's decision. 3. Transaction aimed at improving treatment for aortic regurgitation patients. 4. Trilogy THV System limited to investigational use in the U.S.

M&A
-0.59%Current Return
VS
-0.09%S&P 500
$78.3908/06 02:22 PM EDTEvent Start
$77.9308/07 09:26 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bearish?

FTC's blocking of the acquisition may hinder growth prospects for Edwards, similar to previous FTC actions leading to stock downturns in similar situations.

How important is it?

The potential acquisition's blockage directly impacts Edwards' growth strategy, making it a significant concern for investors.

Why Short Term?

The immediate legal proceedings could create volatility for Edwards in the coming months, as similar companies often experience short-term price fluctuations due to regulatory hurdles.

Related Companies

EWTRSSYK
August 06, 2025 14:17 ET  | Source: JenaValve Technology, Inc. IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company’s proposed acquisition by Edwards Lifesciences. JenaValve respectfully disagrees with the FTC's decision and remains committed to completing the acquisition. JenaValve remains confident in both its rationale for the transaction and the value it will bring to the hundreds of thousands of patients suffering from aortic regurgitation. JenaValve intends to join Edwards to defend this case in court to complete the acquisition. About JenaValveJenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative THV solutions for the treatment of patients suffering from heart valve disease. The Company's Trilogy THV System is a TAVR system designed to treat patients with symptomatic, severe AR, and symptomatic, severe aortic stenosis who are at high surgical risk. The Trilogy THV System received CE Mark approval, providing European physicians with the first TAVR device with true dual-disease treatment capabilities. In the US, the Trilogy THV System is limited to investigational use only. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, United Kingdom, and Munich, Germany. JenaValve is backed by Bain Capital Life Sciences, Andera Partners, Valiance Life Sciences, Rosetta Capital, Cormorant Asset Management, Legend Capital, NeoMed Management, RMM, VI Partners, Pictet Alternative Advisors SA, Qatar Investment Authority (QIA), Innovatus Capital Partners, and Peijia Medical Limited. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. Additional information is available at www.jenavalve.com. JenaValve Contact:Daniel Sundsun@jenavalve.com

Related News